FS-207

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameFS-207
Drug Alias NameFS-207FS207
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBifunctional 3'-5' exonuclease/ATP-dependent helicase WRN inhibitors
TargetsBifunctional 3'-5' exonuclease/ATP-dependent helicase WRN
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesFushi Biotechnology (Hefei) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFushi Biotechnology (Hefei) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A